← 返回

白藜芦醇对 T 细胞氧化代谢和抗肿瘤功能的有益作用取决于先前体内 T 细胞历史

英文原题:Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by prior in vivo T cell history.

查看英文原题

Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by prior in vivo T cell history.

PubMed 2025/08/11(内容时间) Mol Ther Methods Clin Dev Q2 · IF 5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

尽管在癌症过继性细胞免疫治疗中,重定向T细胞取得了临床成功,但患者可能对治疗表现出耐药性,导致疾病失控和复发。这一现象部分源于体外生产的T细胞代谢适应性受损,包括呼吸储备下降,以及对肿瘤介导的代谢应激更为敏感。为了提高培养T细胞的呼吸能力,我们试图通过在培养基中添加白藜芦醇来靶向烟酰胺腺嘌呤二核苷酸/沉默信息调节因子1/活性氧(ROS)轴。经白藜芦醇处理的T细胞表现出更广泛的呼吸能力,同时具有持续的ROS控制能力。引人注目的是,我们揭示白藜芦醇对T细胞的作用仅限于巨细胞病毒(CMV)暴露的供者,该病毒已知会促进免疫衰老。

在此,CMV既往感染与终末分化T细胞对伴随T细胞亚群命运的影响相关。此外,除了白藜芦醇对重定向T细胞代谢特征的影响外,在第三代CD123特异性CAR-T 细胞体外模型中,它还为这些CMV血清阳性供者来源的T细胞提供了功能性抗肿瘤优势。这凸显了在评估新的T细胞生产工艺以提高临床疗效时,必须考虑患者的内在属性,尤其是免疫衰老相关属性,从而推动个性化医疗的极限。

展开英文摘要原文

Despite the clinical success of redirected T cells in the setting of cancer adoptive cell immunotherapy, patients may exhibit resistance to treatment, resulting in uncontrolled disease and relapses. This phenomenon partly relies on impaired ex vivo -produced T cell metabolic fitness, including a decreased respiratory reserve, as well as a greater sensitivity to tumor-mediated metabolic stress.

To improve the respiratory capacity of cultured T cells, we sought to target the nicotinamide adenine dinucleotide/sirtuine-1/reactive oxygen species (ROS) axis through supplementation of culture medium with resveratrol. Resveratrol-treated T cells display broader respiratory capacities, along with sustained ROS control ability. Strikingly, we reveal that the effect of resveratrol on T cells is restricted to cytomegalovirus (CMV)-exposed donors, a virus known to promote immune aging.

Herein, CMV prior infection is associated with the influence of terminally differentiated T cells on the fate of companion T cell subsets.

Moreover, beyond resveratrol's effect on redirected T cell metabolic features, it provides a functional anti-tumor advantage to these CMV-seropositive donor-derived T cells, in a third-generation CD123-specific chimeric antigen receptor-T cell in vitro model. This highlights the necessity to consider patient's intrinsic attributes, especially immune aging-related ones, when assessing new T cell production processes to improve clinical efficacy, pushing the limits of personalized medicine.

论文信息

作者
Mercier-Letondal P、Marton C、Royer B、Peixoto P、Dehecq B、Adotévi O、Galaine J、Godet Y
单位
UMR 1098 RIGHT INSERM/Etablissement Français du Sang Bourgogne Franche-Comté/Université Marie et Louis Pasteur, 25000 Besançon, France.France
期刊
Molecular therapy. Methods & clinical development2025 Sep 11
原文标识
PubMed 40917691 · DOI 10.1016/j.omtm.2025.101553